ASCO 2015 | Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer
Thomas Powles
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the updated response and survival data of a phase 1a study of the anti-PDL1 antibody, MPDL3280A, for the treatment of patients with metastatic urothelial bladder cancer.
Related videos
2:43 Targeted screening and risk stratification of prostate cancer - updates from the IMPACT study
Rosalind Eeles
2:36 Erdafitinib and hyperphosphatemia in advanced UrC
Scott Tagawa
3:04 Kidney cancer: minimizing toxicities and hassle in adjuvant therapy
Tim Eisen
3:56 TROPHY-U-01: Initial findings
Scott Tagawa
2:34 Updates on JAVELIN renal 101: primary treatment for patients
Laurence Albiges
